Compare Stocks: CRDL, THCX, and GUD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$2.16 -0.5%	$1.44	$0.88 ▼ $2.28	$252.11M	0.79	1.62 million shs	976,170 shs
GUD Knight Therapeutics	C$10.04 +3.8%	C$9.71	C$5.66 ▼ C$10.17	C$949.90M	-0.290935	97,945 shs	488,532 shs
THCX AXS Cannabis ETF	$16.60	$16.60	$14.90 ▼ $25.40	$141.07M	1.71	15,071 shs	N/A

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	-0.46%	+4.85%	+58.82%	+94.59%	+98.17%
GUD Knight Therapeutics	+3.83%	+4.69%	+7.49%	+16.61%	+55.18%
THCX AXS Cannabis ETF	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$2.16 -0.5%	$1.44	$0.88 ▼ $2.28	$252.11M	0.79	1.62 million shs	976,170 shs
GUD Knight Therapeutics	C$10.04 +3.8%	C$9.71	C$5.66 ▼ C$10.17	C$949.90M	-0.290935	97,945 shs	488,532 shs
THCX AXS Cannabis ETF	$16.60	$16.60	$14.90 ▼ $25.40	$141.07M	1.71	15,071 shs	N/A

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	-0.46%	+4.85%	+58.82%	+94.59%	+98.17%
GUD Knight Therapeutics	+3.83%	+4.69%	+7.49%	+16.61%	+55.18%
THCX AXS Cannabis ETF	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	362.96% Upside
GUD Knight Therapeutics	3.00	Buy	C$9.50	-5.38% Downside
THCX AXS Cannabis ETF	1.95	Reduce	$16.60	N/A

Current Analyst Ratings Breakdown

Latest CRDL, THCX, and GUD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
7/14/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/24/2026	CRDL Cardiol Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
GUD Knight Therapeutics	C$547.31M	1.80	C$2.61 per share	3.85	C$8.13 per share	1.23
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
GUD Knight Therapeutics	-C$30.73M	C$0.15	66.93	N/A		2.72%	1.91%	0.51%	N/A
THCX AXS Cannabis ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CRDL, THCX, and GUD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/6/2026	Q2 2026	GUD Knight Therapeutics	N/A	-C$0.03	N/A	-C$0.03	N/A	C$143.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
GUD Knight Therapeutics	N/A	N/A	N/A	N/A	N/A
THCX AXS Cannabis ETF	$0.72	4.34%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDL Cardiol Therapeutics	N/A	5.55	5.55
GUD Knight Therapeutics	4.29	2.28	1.79
THCX AXS Cannabis ETF	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDL Cardiol Therapeutics	12.49%
GUD Knight Therapeutics	22.75%
THCX AXS Cannabis ETF	N/A

Insider Ownership

Company	Insider Ownership
CRDL Cardiol Therapeutics	5.25%
GUD Knight Therapeutics	45.62%
THCX AXS Cannabis ETF	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDL Cardiol Therapeutics	20	116.18 million	110.08 million	Not Optionable
GUD Knight Therapeutics	725	98.23 million	N/A	Not Optionable
THCX AXS Cannabis ETF	N/A	8.50 million	N/A	Not Optionable

CRDL, THCX, and GUD Headlines

Recent News About These Companies

The Cannabis M&A Wave Is Here. Curaleaf Proved It.

August 23, 2026 | fool.com

Christina Lake Cannabis Announces Non-Binding Letter of Intent

August 21, 2026 | globenewswire.com

NewLake Capital: Discounted Cannabis REIT Offers Inflation-Beating Yields And Rich Upsides

August 18, 2026 | seekingalpha.com

Village Farms Is Undervalued As International Cannabis Revenue Hits Record Levels

August 11, 2026 | seekingalpha.com

Trulieve Cannabis: First NYSE-Listed Cannabis Stock Is A Buy

August 9, 2026 | seekingalpha.com

Trulieve Cannabis Corp. (TRLV) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Innovative Industrial Properties: Cannabis Rescheduling Progress Reinforces The Re-Rating Thesis

June 30, 2026 | seekingalpha.com

Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement

June 22, 2026 | newsfilecorp.comN

Aurora Cannabis: Weak Near-Term Outlook But Too Cheap To Ignore - Buy

June 12, 2026 | seekingalpha.com

Herbal Dispatch Completes 452kg Multi Client Medical Cannabis Export Shipment To Europe

June 9, 2026 | newsfilecorp.comN

Herbal Dispatch Completes Export of 261kg of Medical Cannabis to Europe

May 21, 2026 | newsfilecorp.comN

Herbal Dispatch Completes Company Record 500kg Medical Cannabis Export Shipment to Europe

May 19, 2026 | newsfilecorp.comN

Aurora Granted Plant Breeders' Rights, Strengthening Leadership in Cannabis Science

May 14, 2026 | prnewswire.com

Village Farms: U.S. Cannabis Optionality (Rating Upgrade)

May 13, 2026 | seekingalpha.com

Green Thumb Industries Will Benefit From Medical Cannabis Rescheduling

May 12, 2026 | seekingalpha.com

Innovative Industrial Properties: Medical Cannabis Rescheduling Implies Bottoming Tenant Default Risks - Reiterate Buy

May 6, 2026 | seekingalpha.com

Herbal Dispatch Launches Next-Generation E-Commerce Platform, Targeting High-Growth $245 Million Insured Medical Cannabis Segment

May 5, 2026 | newsfilecorp.comN

Glow Lifetech Expands Distribution with Two of Canada's Largest Cannabis Retailers, Launches New Product Innovation and Advances National Growth Strategy

April 30, 2026 | newsfilecorp.comN

Cannabis ETFs: Regulatory Momentum Returns Focus

April 30, 2026 | etftrends.comE

Herbal Dispatch Advances U.S. Strategy amid Historic Cannabis Rescheduling Shift

April 27, 2026 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL, THCX, and GUD Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

$2.16 -0.01 (-0.46%)

As of 09/3/2026 04:00 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Knight Therapeutics TSE:GUD

C$10.04 +0.37 (+3.83%)

As of 09/3/2026 04:00 PM Eastern

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca.

AXS Cannabis ETF NYSEARCA:THCX

$16.60 0.00 (0.00%)

As of 03/1/2024

The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRDL, THCX, and GUD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRDL, THCX, and GUD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRDL, THCX, and GUD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL, THCX, and GUD Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

Knight Therapeutics TSE:GUD

AXS Cannabis ETF NYSEARCA:THCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRDL, THCX, and GUD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRDL, THCX, and GUD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRDL, THCX, and GUD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL, THCX, and GUD Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

Knight Therapeutics TSE:GUD

AXS Cannabis ETF NYSEARCA:THCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools